Business
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer
Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment.
About this update from Oncoinvent Asa
[{"type":"text","content":"OSLO, Norway, Aug. 27, 2025 /PRNewswire/ -- Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment.","length":201,"tagName":"p"},{"type":"text","content":"Highlights for the first half of 2025:","length":38,"tagName":"p"},{"type":"text","content":"Radspherin®","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Positive final data from Phase1/2a trial in colorectal cancer patients","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive interim 18-months data from Phase1 trial in ovarian cancer patients","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive read-out of safety lead-in cohort and opening of randomized part of Phase 2 trial in ovarian cancer patients","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory approvals for additional sites for the randomized Phase 2 trial in ovarian cancer, with expected onboarding before end of 2025","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":400,"olType":false},{"type":"text","content":"Corporate","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Operating expenses reduced by 28% versus last year","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"Merger with BerGenBio","length":21,"tagName":"p"}]},{"val":[{"type":"text","content":"Fully guaranteed rights issue of NOKm 130","length":41,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":112,"olType":false},{"type":"text","content":"CEO Øystein Soug and CFO Tore Kvam will present the results for the first half of 2025 at a webcast available at https://channel.royalcast.com/landingpage/hegnarmedia/20250827_3/, Wednesday 27 August at 08:00 CEST. The presentation and Q&A will be held in English. A recording of the webcast will be made available on our website shortly after the presentation.","length":365,"tagName":"p"},{"type":"text","content":"About Oncoinvent","length":16,"tagName":"p"},{"type":"text","content":"Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surge...